학술논문

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Document Type
Article
Source
In Annals of Oncology May 2021 32(5):609-619
Subject
Gastrointestinal tumors
Language
ISSN
0923-7534